RDB12872 - CSIV-RfA-TRE-EF-KT

CSIV-RfA-TRE-EF-KT (#RDB12872)

Backbone vector plasmid of lentivirus construct driven by Tet-responsive promoter by Gateway(R) cloning with hKO1-2A-rtTA marker driven by EF-1 alpha promoter.

Drawn by SnapGene® software

Sequence information (Assembled from experimentally sequenced data)	GenBank Flat File Format open
	SnapGene file download
Publication	Iida, T., Stem Cells 35 (5): 1316-1327 (2017). PMID 28142229. [PubMed] [Article] [RRC of NBRP]
Test sheet	Data Sheet open

Clone info.	Backbone vector plasmid of lentivirus construct driven by Tet-responsive promoter by Gateway(R) cloning with hKO1-2A-rtTA marker driven by EF-1 alpha promoter. Please note that the TRE and EF promoters are placed in back-to-back orientation and this construct contains loxP.
Comment	Commonly requested with pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394).
Vector backbone	CSIV-RfA-TRE-EF-KT (Plasmid)
Selectable markers	Ampicillin (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Growth remarks	Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30 degC is fine.
Depositor\|Developer	Miyoshi, Hiroyuki \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link]

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).

Remarks Remember that you will be working with samples containing infectious virus.
Use Survival2 (Invitrogen) or equivalent to amplify this clone.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Ordering instruction.[link]
Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).
Remarks	Remember that you will be working with samples containing infectious virus. Use Survival2 (Invitrogen) or equivalent to amplify this clone.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。付加的使用条件： When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).
備考	このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。このクローンの増殖にはSurvival2 (Invitrogen)あるいは同等の宿主を使用してください。

Catalog #	Resource name	Shipping form	Fee
RDB12872	CSIV-RfA-TRE-EF-KT	DNA solution	JPY 9,460 (not-for-profit academic purpose) plus cost of shipping containers, dry ice (if required) and shipping charge

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSIV-RfA-TRE-EF-KT was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB12872).

Reference section:

Iida, T., Iwanami, A., Sanosaka, T., Kohyama, J., Miyoshi, H., Nagoshi, N., Kashiwagi, R., Toyama, Y., Matsumoto, M., Nakamura, M., Okano, H., Whole-Genome DNA Methylation Analyses Revealed Epigenetic Instability in Tumorigenic Human iPS Cell-Derived Neural Stem/Progenitor Cells. Stem Cells 35 (5): 1316-1327 (2017). PMID 28142229. [PubMed] [Article] [RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

original	Iida, T., Whole-Genome DNA Methylation Analyses Revealed Epigenetic Instability in Tumorigenic Human iPS Cell-Derived Neural Stem/Progenitor Cells. Stem Cells 35 (5): 1316-1327 (2017). PMID 28142229. [PubMed] [Article] [RRC of NBRP]
reference	Kojima, K., Selective Ablation of Tumorigenic Cells Following Human Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cell Transplantation in Spinal Cord Injury. Stem Cells Transl. Med. 8 (3): 260-270 (2019). PMID 30485733. [PubMed] [Article]
reference	Iwasawa, C., Increased Cytotoxicity of Herpes Simplex Virus Thymidine Kinase Expression in Human Induced Pluripotent Stem Cells. Int. J. Mol. Sci. 20 (4). pii: E810 (2019). PMID 30769780. [PubMed] [Article]
reference	Yoshimatsu, S., Evaluating the efficacy of small molecules for neural differentiation of common marmoset ESCs and iPSCs. Neurosci. Res. pii: S0168-0102 (19) 30262-7 (2019). PMID 31586586. [PubMed] [Article]
reference	Kwon, S.J., Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii. Mol. Cancer 16 (1): 140 (2017). PMID 28830458. [PubMed] [Article]

Resource search

Link

Other resources in our bank

External Database

Reference sequence